← board
NXTS
distress 6/10 · elevated risk$1.88-9%today-98% from 52w high
Revenue
pre-revenue
Liquidity
$6M
Runway
1.4 yrs
Shares 1y
-98%
Price & events
-85.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-9.0%
1D
-24.4%
1W
-67.7%
1M
-62.6%
3M
-83.6%
6M
-97.2%
1Y
-98.4%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $1.37M
- Volume
- 24.39K
- 52 Week Range
- $1.88 – $82.32
- Total Shares
- 730.46K
- Float Shares
- 448.19K
- Short %
- 7.27%
- % Held by Insiders
- 22.65%
- % Held by Institutions
- 1.11%
- RVOL
- 0.01x
- Beta
- 1.82
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2025-10-20partnershipMitoCareX · Acquisition of MitoCareX Bio Ltd. completedSEC 8-K
- 2025-09-25partnershipStockholders approve acquisition of MitoCareX, a drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer.SEC 8-K
- 2025-02-25partnershipN2OFF acquires MitoCareX via securities purchase and exchange agreement.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.